INVESTOR OVERVIEW

Corporate Profile

Rhythm is a biopharmaceutical company focused on developing and commercializing peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. More >>

Recent NewsMore >>
01/04/18
Rhythm Pharmaceuticals Announces Progress in Clinical Development of Setmelanotide for Treatment of Rare Genetic Disorders of Obesity
11/14/17
Rhythm Pharmaceuticals Reports Third Quarter 2017 Financial Results
10/31/17
Rhythm Announces Preliminary Data from Phase 2 Study of Setmelanotide for Treatment of Bardet-Biedl Syndrome
RYTM (Common Stock) $26.050.00 (0.00%)02/21/18 4:00 p.m. ET
Stock chart for: RYTM.O.  Currently trading at $26.05 with a 52 week high of $33.81 and a 52 week low of $21.38.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources
Upcoming EventsMore >>
There are currently no events scheduled.